© 2016

Novel Biomarkers in the Continuum of Breast Cancer

  • Vered Stearns

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 882)

Also part of the Breast Cancer Research Foundation book sub series (BCRF, volume 882)

Table of contents

  1. Front Matter
    Pages i-xix
  2. Michael F. Walsh, Katherine L. Nathanson, Fergus J. Couch, Kenneth Offit
    Pages 1-32
  3. Mary Beth Terry, Jasmine A. McDonald, Hui Chen Wu, Sybil Eng, Regina M. Santella
    Pages 33-68
  4. Carol J. Fabian, Bruce F. Kimler
    Pages 69-94
  5. Omar Mahmoud, Bruce G. Haffty
    Pages 95-124
  6. Vinay Varadan, Maria Sandoval, Lyndsay N. Harris
    Pages 155-167
  7. Francisco Beca, Kornelia Polyak
    Pages 169-189
  8. Daniel L. Hertz, James M. Rae
    Pages 191-215
  9. Christopher D. Hart, Leonardo Tenori, Claudio Luchinat, Angelo Di Leo
    Pages 217-234
  10. Costanza Paoletti, Daniel F. Hayes
    Pages 235-258
  11. Heather A. Parsons, Julia A. Beaver, Ben H. Park
    Pages 259-276
  12. Back Matter
    Pages 277-279

About this book


This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research.

Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.


Anti HER2 agents Epigenetics breast cancer research foundation breast cancer therapeutics genetic biomarkers

Editors and affiliations

  • Vered Stearns
    • 1
  1. 1.Johns Hopkins UniversitySidney Kimmel Comprehensive Cancer Ctr.BALTIMOREUSA

About the editors

Vered Stearns is a Professor of Oncology and the Co-Director of the Breast and Ovarian Cancer Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, where she also holds the Breast Cancer Research Chair in Oncology. Dr. Stearns is an expert in novel drug investigation—her long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. Her main research includes utilization of biomarkers to predict response to standard regimens used to treat and prevent breast cancer and to introduce new treatments. While administering standard chemotherapy in the preoperative setting, Dr. Stearns examines molecular markers and functional imaging to assist in the early determination of sensitivity or resistance to different treatments. Dr. Stearns and colleagues from the Consortium On Breast Cancer Pharamcogenomics (COBRA) were the first to evaluate the role of genetic variants in candidate genes such as CYP2D6 in tamoxifen metabolism, safety, and efficacy. The work has been extended to evaluate the role of genetic variants in aromatase inhibitor-associated outcomes. Dr. Stearns, who received numerous grants and awards to fund her innovative research, was a recipient of early career awards, including a Clinical Research Training Grant from the American Cancer Society, and was one of the first five recipients of the prestigious Damon Runyon Clinical Investigator Award. Subsequently, she was the inaugural recipient of the American Society of Clinical Oncology’s Advanced Clinical Research Award. She is an Editorial Board Member of Clinical Cancer Research, Breast Cancer Research and Treatment, and ONCOLOGY. Dr. Stearns’ work has been presented in key national and international meetings. She has published more than 150 scientific publications, which have been cited extensively.

Bibliographic information

  • Book Title Novel Biomarkers in the Continuum of Breast Cancer
  • Editors Vered Stearns
  • Series Title Advances in Experimental Medicine and Biology
  • Series Abbreviated Title Adv Exp Med Biol
  • DOI
  • Copyright Information Breast Cancer Research Foundation 2016
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-319-22908-9
  • Softcover ISBN 978-3-319-79434-1
  • eBook ISBN 978-3-319-22909-6
  • Series ISSN 0065-2598
  • Series E-ISSN 2214-8019
  • Edition Number 1
  • Number of Pages XIX, 279
  • Number of Illustrations 30 b/w illustrations, 4 illustrations in colour
  • Topics Cancer Research
    Human Genetics
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods